Qiagen N.V. Stock News

SAN DIEGO--(BUSINESS WIRE)--Element Biosciences Partners with QIAGEN to Validate a Selection of QIAseq Targeted Library Construction Chemistries on Elements AVITI System

WASHINGTON, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the Global Epigenetics Market finds that increasing cancer rates may further expediting market growth. Primarily driven by increasing research activity and funding for Epigenetics, the total Global Epigenetics Market is estimated to reach USD 3.0 Billion by 2028. The market stood at a revenue of USD 0.8 Billion in the year 2021, and is expected to grow at a Compound Annual Growth Rate (CAGR) of 13.1%. Furthermore, the increasing personalized medication, and target therapy are also anticipated to augment the growth of the Global Epigenetics Market, states Vantage Market Research, in a report, titled " Epigenetics Market by Product (Instruments, Reagents & Kits, Others), by Application (Oncology, Autoimmune Diseases, Metabolic Diseases, CNS/Pain Diseases), by Technology (Methylation, Acetylation, Phosphorylation, Other Technologies), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".

Pune, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Global Digital PCR (dPCR) and Real-Time PCR (qPCR) Market report delivers a complete overview of key components like drivers, limitations, historic and current trends, technical development, and future growth. Research report contains company analysis, size, share, revenue and sales of the company, current advancements. Digital PCR and Real-Time PCR market analysis also focuses on the global key top industry players in the market, with details such as company profiles, capacity, production, price, cost, revenue. Get a Sample Copy of the Report at - https://www.absolutereports.com/enquiry/request-sample/20190575 The global Digital PCR and Real-Time PCR market size is projected to reach USD 1879.8 million by 2028, from USD 1180.1 million in 2021, at a CAGR of 6.8% during 2022-2028.  Polymerase chain reaction (PCR) is a laboratory technique performed commonly to amplify DNA, thereby producing many copies of a particular section of DNA in interest.

Is QIAGEN (QGEN) a great pick from the value investor's perspective right now? Read on to know more.

Las Vegas, USA, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Molecular Diagnostics Market is Expected to Grow at a Substantial CAGR of 9.21% and is Contemplated to Reach USD 16.12 Billion by 2026, Estimates DelveInsight Molecular Diagnostics Market is contemplated to witness huge demand in the upcoming years due to rising infectious diseases and their diagnosis, the presence of global as well as regional manufacturers active in developing the Molecular Diagnostic products such as Qiagen, Roche, Molbio Diagnostics Pvt. Ltd., among others. Also, improving healthcare infrastructure, government initiatives in raising awareness regarding molecular diagnosis will contribute to the Molecular Diagnostics market growth in these regions. DelveInsight''s Molecular Diagnostics Market Insights and Forecast report provides the current and forecast Molecular Diagnostics Market, upcoming innovation in the devices, individual market shares, challenges, drivers and barriers, market trends, and key competitors in the Molecular Diagnostics Market.

QIA gives financial backing to Bodhi Tree Investment Platform, a strategic partnership Of Lupa Systems And Uday Shankar. Bodhi Tree to focus on media and consumer

James Murdoch and Uday Shankars, two well known names in the media

James Murdoch and Uday Shankar have formed Bodhi Tree, an investment platform financially supported by the Qatar Investment Authority (QIA) designed to invest in media and consumer technology opportunities in Southeast Asia, with a particular focus on India. Murdoch set up Lupa Systems as a private holding company in 2019 following his departure as CEO […]

This new venture is designed to invest in media and consumer technology opportunities in Southeast Asia, with a particular focus on India, the two partners said in a statement.

QIA will be committing up to $1.5 billion in Bodhi Tree''s vision being pursued by Murdoch and Shankar

High demand for COVID-19 test products and improving trends in the non-COVID portfolio drove QIAGEN's (QGEN) fourth-quarter revenues.

QIAGEN N.V. (QGEN) CEO Thierry Bernard on Q4 2021 Results - Earnings Call Transcript

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Humanigen Announces Agreement With French CDMO For Fill And Finish Services For Lenzilumab Humanigen,